| In millions, except per share items | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Impax Generics | 549.1 | 606.3 | 710.9 | 549.1 | 398.3 | | | |
| Impax Specialty Pharma | 226.7 | 218.1 | 149.5 | 47.0 | 113.2 | | | |
| Total revenues | 775.8 | 824.4 | 860.5 | 596.0 | 511.5 | 581.7 | 512.9 | 879.5 |
| Revenue growth [+] | -5.9% | -4.2% | 44.4% | 16.5% | -12.1% | 13.4% | -41.7% | 145.4% |
| Impax Generics | -9.4% | -14.7% | 29.5% | 37.8% | | | | |
| Impax Specialty Pharma | 3.9% | 45.9% | 218.4% | -58.5% | | | | |
| Cost of goods sold | 535.1 | 486.9 | 500.8 | 280.5 | 312.2 | 299.1 | 254.6 | 340.2 |
| Gross profit | 240.7 | 337.5 | 359.7 | 315.5 | 199.3 | 282.6 | 258.3 | 539.3 |
| Gross margin | 31.0% | 40.9% | 41.8% | 52.9% | 39.0% | 48.6% | 50.4% | 61.3% |
| Selling, general and administrative | 216.3 | 201.8 | 201.3 | 139.4 | 120.3 | 108.5 | 68.5 | 53.3 |
| Research and development | 80.8 | 80.5 | 70.6 | 78.6 | 68.9 | 81.3 | 82.7 | 86.2 |
| Other operating expenses | -338.0 | 0.8 | -45.6 | 5.8 | 16.5 | 9.8 | 7.5 | 6.4 |
| EBITDA [+] | 391.0 | 142.8 | 202.0 | 125.7 | 29.6 | 160.9 | 115.3 | 406.0 |
| EBITDA growth | 173.8% | -29.3% | 60.7% | 324.5% | -81.6% | 39.5% | -71.6% | 397.1% |
| EBITDA margin | 50.4% | 17.3% | 23.5% | 21.1% | 5.8% | 27.7% | 22.5% | 46.2% |
| Depreciation | 41.1 | 31.9 | 28.4 | 22.9 | 36.0 | 59.1 | 15.7 | 12.7 |
| EBITA | 349.9 | 111.0 | 173.6 | 102.8 | -6.4 | 101.8 | 99.6 | 393.3 |
| EBITA margin | 45.1% | 13.5% | 20.2% | 17.2% | -1.2% | 17.5% | 19.4% | 44.7% |
| Amortization of intangibles | 68.4 | 56.5 | 40.2 | 11.1 | | 18.8 | | |
| EBIT [+] | 281.5 | 54.5 | 133.4 | 91.7 | -6.4 | 83.0 | 99.6 | 393.3 |
| EBIT growth | 416.9% | -59.2% | 45.5% | -1535.6% | -107.7% | -16.7% | -74.7% | 458.6% |
| EBIT margin | 36.3% | 6.6% | 15.5% | 15.4% | -1.2% | 14.3% | 19.4% | 44.7% |
| Non-recurring items [+] | 684.2 | 548.6 | 63.8 | 2.9 | | | | |
| Asset impairment | 661.9 | 541.6 | 13.7 | 2.9 | | | | |
| Loss (gain) on sale of assets | 17.2 | 0.2 | 45.6 | | | | | |
| Legal settlement | 5.1 | 7.8 | 4.6 | | | | | |
| Loss on contingent liability | -31.0 | | | | | | | |
| Interest expense, net [+] | 53.4 | 40.4 | 26.2 | -1.4 | -0.9 | -0.5 | -1.0 | -0.9 |
| Interest expense | 53.4 | 40.4 | 26.2 | 0.0 | 0.4 | 0.6 | 0.2 | 0.2 |
| Interest income | | | | 1.5 | 1.3 | 1.1 | 1.1 | 1.0 |
| Other income (expense), net [+] | 5.1 | -41.7 | 16.0 | 0.3 | 152.4 | -0.1 | -2.5 | -0.3 |
| Gain (loss) on debt retirement | -1.2 | | -16.9 | | | | | |
| Gain (loss) on derivative instruments | | | -13.0 | | | | | |
| Other | -6.9 | -1.6 | 0.4 | 0.3 | 152.4 | -0.1 | -2.5 | -0.3 |
| Pre-tax income | -451.0 | -576.3 | 59.4 | 90.6 | 146.9 | 83.3 | 98.1 | 393.9 |
| Income taxes | 18.3 | -104.3 | 20.4 | 33.2 | 45.7 | 27.4 | 32.6 | 143.5 |
| Tax rate | | 18.1% | 34.3% | 36.7% | 31.1% | 32.9% | 33.2% | 36.4% |
| Net income | -469.3 | -472.0 | 39.0 | 57.4 | 101.3 | 55.9 | 65.5 | 250.4 |
| Net margin | -60.5% | -57.3% | 4.5% | 9.6% | 19.8% | 9.6% | 12.8% | 28.5% |
| |
| Basic EPS [+] | ($6.53) | ($6.63) | $0.56 | $0.84 | $1.51 | $0.85 | $1.02 | $4.04 |
| Growth | -1.6% | -1284.8% | -33.4% | -44.4% | 77.8% | -16.7% | -74.7% | 386.0% |
| Diluted EPS [+] | ($6.53) | ($6.63) | $0.54 | $0.81 | $1.47 | $0.82 | $0.97 | $3.82 |
| Growth | -1.6% | -1325.4% | -33.4% | -44.9% | 80.6% | -16.0% | -74.5% | 366.0% |
| |
| Shares outstanding (basic) [+] | 71.9 | 71.1 | 69.6 | 68.2 | 66.9 | 65.7 | 64.1 | 62.0 |
| Growth | 1.0% | 2.2% | 2.1% | 1.9% | 1.9% | 2.4% | 3.4% | 2.9% |
| Shares outstanding (diluted) [+] | 71.9 | 71.1 | 72.0 | 70.5 | 68.7 | 68.4 | 67.3 | 65.6 |
| Growth | 1.0% | -1.2% | 2.1% | 2.7% | 0.4% | 1.6% | 2.7% | 7.3% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |